Synapse

← Current Drug Targets - Immune Endocrine & Metabolic Disorders

Papers in Current Drug Targets - Immune Endocrine & Metabolic Disorders

Page 1 · newest first

  1. Hormonal Effects on Drug Metabolism Through the CYP System: Perspectives on Their Potential Significance in the Era of PharmacogenomicsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  2. Insulin Regulation of PEPCK Gene Expression: A Model for Rapid and Reversible ModulationCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  3. Molecular Basis of Therapeutic Strategies for Breast CancerCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  4. Failure of Immune Homeostasis - The Consequences of Under and Over ReactivityCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  5. Signal Transducer and Activator of Transcription 5 (STAT5), a Crucial Regulator of Immune and Cancer CellsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  6. Role of FXR in Regulating Bile Acid Homeostasis and Relevance for Human DiseasesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  7. Caspases as Drug Targets in Ischemic Organ InjuryCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  8. Advances in Osteoclast Differentiation and FunctionCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  9. Signaling Processes in Tumoral Neuroendocrine Pituitary Cells as Potential Targets for Therapeutic DrugsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  10. Myocardial Insulin Resistance and Cardiac Complications of DiabetesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  11. Contribution of Canalicular Glutathione Efflux to Bile Formation. From Cholestasis Associated Alterations to Pharmacological Intervention to Modify Bile FlowCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  12. Ion Transport Across the Gallbladder EpitheliumCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  13. Effects of Endocrine Disruptors on Developmental and Reproductive FunctionsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  14. Reduction of Hepatic Glucose Production as a Therapeutic Target in the Treatment of DiabetesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  15. CXCR3-binding Chemokines: Novel Multifunctional Therapeutic TargetsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  16. Therapeutic Strategies To Prevent Neurodegeneration And Promote Regeneration In Multiple SclerosisCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  17. Regulation of the Steroidogenic Acute Regulatory Protein Expression: Functional and Physiological ConsequencesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
  18. Recent Advances in the Understanding of HIV-1 Vpu Accessory Protein FunctionsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  19. Chemokine-Chemokine Receptor Network in Immune Cell TraffickingCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  20. Functions of the HIV-1 Nef ProteinCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  21. Therapeutic Targeting of Interactions Between Nef and Host Cell ProteinsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  22. The Impact of Body Mass Index and Type 2 Diabetes on Breast Cancer: Current Therapeutic Measures of PreventionCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  23. Controlling HIV-1 Rev FunctionCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  24. Molecular Elements of Apoptosis-Regulating Pathways in Follicular Thyroid Cells: Mining for Novel Therapeutic Targets in the Treatment of Thyroid CarcinomaCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  25. Redifferentiation Therapy in Advanced Thyroid CancerCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  26. Activins, Myostatin and Related TGF-β Family Members as Novel Therapeutic Targets for Endocrine, Metabolic and Immune DisordersCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  27. The Pathobiology of Osteoarthritis and the Rationale for Using the Chondroitin Sulfate for its TreatmentCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  28. Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill PatientsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  29. Regulators of G Protein Signaling: Potential Drug Targets for Controlling Cardiovascular and Immune FunctionCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  30. Immunological Modulation by Lidocaine-Epinephrine and Prilocaine- Felypressin on the Functions Related to Natural Immunity in Neutrophils and MacrophagesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  31. The HIV-1 Nef Protein: How An AIDS Pathogenetic Factor Turns to a Tool for Combating AIDSCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  32. HDL and Inflammation in AtherosclerosisCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  33. DI-2-Ethylhexyl Phthalate and Endocrine Disruption: A ReviewCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  34. CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for TherapyCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  35. Evidence for a Putative Relationship Between Type 2 Diabetes and Neoplasia with Particular Reference to Breast Cancer: Role of Hormones, Growth Factors and Specific ReceptorsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  36. Melatonin Role in Experimental ArthritisCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
  37. Tissue-Specific Glucocorticoid Reactivating Enzyme, 11β-Hydroxysteoid Dehydrogenase Type 1 (11β-HSD1) - A Promising Drug Target for the Treatment of Metabolic SyndromeCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  38. Dual Roles of Adiponectin / Acrp30 In Vivo as an Anti-Diabetic and Anti- Atherogenic AdipokineCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  39. Protein-Tyrosine Phosphatase 1B as a Potential Drug Target for ObesityCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  40. DGAT: Novel Therapeutic Target for Obesity and Type 2 Diabetes MellitusCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  41. Physiological Roles of Glycogen Synthase Kinase-3: Potential as a Therapeutic Target for Diabetes and Other DisordersCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  42. Stearoyl-CoA Desaturase-1 and the Metabolic SyndromeCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  43. Evidences for iNOS Expression and Nitric Oxide Production in the Human MacrophagesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  44. Breast Cancer: Biological Characteristics in Postmenopausal Type 2 Diabetic Women. Identification of Therapeutic TargetsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  45. Skin Photoprotection by Green Tea: Antioxidant and Immunomodulatory EffectsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  46. Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic AgentsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  47. Do Antidotes for Acute Cyanide Poisoning Act on Mercaptopyruvate Sulfurtransferase to Facilitate Detoxification?Current Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  48. Biosynthetic Pathways of Plastid-Derived Organelles as Potential Drug Targets Against Parasitic ApicomplexaCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  49. Metformin and its Liver Targets in the Treatment of Type 2 DiabetesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
  50. Drug-Induced Aseptic MeningitisCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003